Vitamins in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results COVIT-TRIAL, 2022 0.54 [0.22; 1.34]
0.54 [0.22 ; 1.34 ] COVIT-TRIAL, 2022 1 0% 254 NA not evaluable death D28detailed results COVIT-TRIAL, 2022 0.89 [0.45; 1.75]
Zhang, 2020 0.50 [0.17; 1.50]
0.76 [0.43 ; 1.35 ] COVIT-TRIAL, 2022, Zhang, 2020 2 0% 308 serious not evaluable deathsdetailed results Cao, 2020 0.15 [0.01; 3.29]
COVID-VIT-D, 2022 1.48 [0.75; 2.92]
COVIT-TRIAL, 2022 0.89 [0.45; 1.75]
Entrenas (Pilot Calcifediol), 2020 0.12 [0.01; 2.79]
Jamali Moghadam Siahkali, 2021 1.00 [0.19; 5.40]
Kumari, 2020 0.60 [0.22; 1.64]
Murai, 2020 1.53 [0.53; 4.43]
Zhang, 2020 0.50 [0.17; 1.50]
0.92 [0.62 ; 1.35 ] Cao, 2020, COVID-VIT-D, 2022, COVIT-TRIAL, 2022, Entrenas (Pilot Calcifediol), 2020, Jamali Moghadam Siahkali, 2021, Kumari, 2020, Murai, 2020, Zhang, 2020 8 7% 1,415 moderate serious deaths (time to event analysis only)detailed results Zhang, 2020 0.50 [0.17; 1.50]
0.50 [0.17 ; 1.50 ] Zhang, 2020 1 0% 56 NA not evaluable clinical deteriorationdetailed results Cao, 2020 0.11 [0.01; 2.21]
Zhang, 2020 0.87 [0.23; 3.27]
0.49 [0.08 ; 3.03 ] Cao, 2020, Zhang, 2020 2 35% 97 moderate not evaluable clinical improvementdetailed results Cao, 2020 1.67 [0.84; 3.33]
1.67 [0.84 ; 3.33 ] Cao, 2020 1 0% 42 NA not evaluable clinical improvement (14-day)detailed results Cao, 2020 2.00 [0.58; 6.94]
2.00 [0.58 ; 6.94 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (21-day)detailed results Cao, 2020 1.50 [0.22; 10.08]
1.50 [0.22 ; 10.08 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (7-day)detailed results Cao, 2020 2.38 [0.38; 14.70]
2.38 [0.38 ; 14.70 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.67 [0.84; 3.33]
1.67 [0.84 ; 3.33 ] Cao, 2020 1 0% 42 NA not evaluable hospital dischargedetailed results Murai, 2020 0.99 [0.71; 1.38]
0.99 [0.71 ; 1.38 ] Murai, 2020 1 0% 240 NA not evaluable mechanical ventilationdetailed results Jamali Moghadam Siahkali, 2021 1.30 [0.31; 5.40]
Kumari, 2020 0.76 [0.33; 1.76]
Murai, 2020 0.49 [0.21; 1.14]
0.68 [0.39 ; 1.19 ] Jamali Moghadam Siahkali, 2021, Kumari, 2020, Murai, 2020 3 0% 447 low not evaluable radiologic improvement (14-day)detailed results Cao, 2020 5.54 [1.01; 30.50]
5.54 [1.01 ; 30.50 ] Cao, 2020 1 0% 41 NA not evaluable viral clearance detailed results Rastogi, 2020 6.33 [1.54; 26.00]
6.33 [1.54 ; 26.00 ] Rastogi, 2020 1 0% 40 NA not evaluable ICU admissiondetailed results Entrenas (Pilot Calcifediol), 2020 0.03 [0.00; 0.27]
Murai, 2020 0.71 [0.37; 1.37]
0.17 [0.01 ; 3.79 ] Entrenas (Pilot Calcifediol), 2020, Murai, 2020 2 86% 313 moderate not evaluable serious adverse eventsdetailed results Cao, 2020 0.11 [0.01; 2.21]
Murai, 2020 0.99 [0.02; 50.39]
0.25 [0.02 ; 2.69 ] Cao, 2020, Murai, 2020 2 0% 278 moderate not evaluable adverse eventsdetailed results Cao, 2020 1.60 [0.38; 6.81]
Murai, 2020 1.99 [0.07; 59.94]
1.65 [0.44 ; 6.27 ] Cao, 2020, Murai, 2020 2 0% 278 moderate not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-08 20:18 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 1244,523,885,734,1439
- roots T: 290
